Jaisim Shah
Chief Executive Officer bei SCILEX HOLDING COMPANY
Vermögen: 179 988 $ am 31.03.2024
Profil
Jaisim Shah is currently the President, Chief Executive Officer & Director at SCILEX Pharmaceuticals, Inc., the Chief Executive Officer at Scilex, Inc., the President, Chief Executive Officer & Director at Scilex Holding Co., and a Director at Sorrento Therapeutics, Inc. Previously, he served as the Chief Executive Officer & Director at Semnur Pharmaceuticals, Inc. from 2013 to 2019.
He also held positions as a Director at Acucela, Inc., Celularity, Inc. (United States), and Bristol Myers Squibb Co. Additionally, he was the Vice President-Global Marketing at Bristol Myers Squibb Co. from 1997 to 2000 and the Senior VP-Marketing & Medical Affairs at Protein Design Labs, Inc. from 2000 to 2006.
Mr. Shah has a graduate degree from the University of Akron and an MBA from the University of Oklahoma.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SCILEX HOLDING COMPANY
0,07% | 04.10.2023 | 112 633 ( 0,07% ) | 179 086 $ | 31.03.2024 |
| 31.01.2023 | 112 633 ( 0,02% ) | 901 $ | 31.03.2024 |
Aktive Positionen von Jaisim Shah
| Unternehmen | Position | Beginn |
|---|---|---|
| SORRENTO THERAPEUTICS, INC. | Director/Board Member | 12.09.2013 |
| SCILEX HOLDING COMPANY | Chief Executive Officer | 09.11.2022 |
Scilex, Inc.
 Scilex, Inc. Pharmaceuticals: MajorHealth Technology Scilex, Inc. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Paolo Alto, CA. | Chief Executive Officer | 01.03.2019 |
SCILEX Pharmaceuticals, Inc.
 SCILEX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SCILEX Pharmaceuticals, Inc. engages in the development and commercialization of pharmaceutical products. It acquires late-stage clinical development and sales and marketing of generic and branded generic products. Its product includes ZTlido. The company was founded by Anthony P. Mack and William Pedranti in 2011 and is headquartered in Berwyn, PA. | Chief Executive Officer | - |
Ehemalige bekannte Positionen von Jaisim Shah
| Unternehmen | Position | Ende |
|---|---|---|
Celularity, Inc. (United States)
 Celularity, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Celularity, Inc. engages in biotechnology company. The firm focuses on the study of placenta. The company was founded in Robert Joseph Hariri Gordon and Peter H. Diamandis in 2016 and is headquartered in Florham Park, NJ. | Director/Board Member | 01.07.2021 |
Semnur Pharmaceuticals, Inc.
 Semnur Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Semnur Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The firm focuses on the clinical and commercial development of products such as SP-102: a non-opioid epidural steroid injectable potentially for the treatment of Lumbosacral radicular pain. The company was founded by Mahendra G. Shah in 2013 and is headquartered in Mountain View, CA. | Chief Executive Officer | 01.03.2019 |
| Elevation Pharmaceuticals, Inc. | Corporate Officer/Principal | 01.01.2012 |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Corporate Officer/Principal | 09.01.2009 |
| PDL BIOPHARMA, INC. | Corporate Officer/Principal | 01.12.2008 |
Ausbildung von Jaisim Shah
| University of Akron | Graduate Degree |
| University of Oklahoma | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| LADRX CORPORATION | Health Technology |
| SORRENTO THERAPEUTICS, INC. | Health Technology |
| SCILEX HOLDING COMPANY | Health Technology |
| Private Unternehmen | 11 |
|---|---|
Protein Design Labs, Inc.
 Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Health Technology |
Azelon Pharmaceuticals, Inc.
 Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | Health Technology |
Pulmatrix Operating Co., Inc.
 Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | Health Technology |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Health Technology |
Semnur Pharmaceuticals, Inc.
Semnur Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Semnur Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The firm focuses on the clinical and commercial development of products such as SP-102: a non-opioid epidural steroid injectable potentially for the treatment of Lumbosacral radicular pain. The company was founded by Mahendra G. Shah in 2013 and is headquartered in Mountain View, CA. | Health Technology |
SCILEX Pharmaceuticals, Inc.
SCILEX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SCILEX Pharmaceuticals, Inc. engages in the development and commercialization of pharmaceutical products. It acquires late-stage clinical development and sales and marketing of generic and branded generic products. Its product includes ZTlido. The company was founded by Anthony P. Mack and William Pedranti in 2011 and is headquartered in Berwyn, PA. | Health Technology |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
Acucela, Inc.
 Acucela, Inc. Pharmaceuticals: MajorHealth Technology Acucela, Inc. operates as a clinical-stage biotechnology company. It discovers and develops novel therapeutics to treat and show the progression of sight-threatening ophthalmic diseases. Its pipeline includes drug candidates and therapeutics for the treatment of age related macular degeneration, cataracts, presbyopia, diabetic retinopathy, retinitis igmentosa and Stargardt disease. The company was founded by Ryo Kubota in April 2002 and is headquartered in Seattle, WA. | Health Technology |
| Elevation Pharmaceuticals, Inc. | Health Technology |
Celularity, Inc. (United States)
Celularity, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Celularity, Inc. engages in biotechnology company. The firm focuses on the study of placenta. The company was founded in Robert Joseph Hariri Gordon and Peter H. Diamandis in 2016 and is headquartered in Florham Park, NJ. | Commercial Services |
Scilex, Inc.
Scilex, Inc. Pharmaceuticals: MajorHealth Technology Scilex, Inc. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Paolo Alto, CA. | Health Technology |
